AA PHASE III, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID¿) IN COMBINATION WITH MELPHALAN AND PREDNISONE VERSUS PLACEBO PLUS MELPHALAN AND PREDNISONE IN SUBJECTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE 65 YEARS OF AGE OR OLDER

Trial Profile

AA PHASE III, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID¿) IN COMBINATION WITH MELPHALAN AND PREDNISONE VERSUS PLACEBO PLUS MELPHALAN AND PREDNISONE IN SUBJECTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE 65 YEARS OF AGE OR OLDER

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Sponsors Celgene Corporation; Celgene International SARL
  • Most Recent Events

    • 27 May 2016 The trial was completed in Greece (end date: 2016-04-13).
    • 11 May 2016 Status changed from active, no longer recruiting to completed.
    • 10 May 2016 The trial was completed in Spain. (end date: 13-Apr-2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top